Trevi Therapeutics Stock (NASDAQ:TRVI)
Previous Close
$2.82
52W Range
$0.97 - $4.00
50D Avg
$3.13
200D Avg
$2.88
Market Cap
$230.60M
Avg Vol (3M)
$436.86K
Beta
1.01
Div Yield
-
TRVI Company Profile
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.